The Genentech Patient Foundation gives free GAZYVA to people who have been prescribed this medicine and don’t have insurance or who have financial concerns and meet certain eligibility criteria.
Your patient may be eligible if their insurance coverage and income match one of these situations:
Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.
If you have any questions about the criteria please contact a Foundation Specialist at 888-941-3331 (Mon.–Fri., 6AM–5PM PST).
For example, a household size of 1 with income of less than $75,000 may meet the criteria for assistance. Add $25,000 for each additional person in the household. There is no maximum number of people you may add.
GAZYVA full Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2022.
GAZYVA full Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2022.
VENCLEXTA® (venetoclax tablets) Prescribing Information. North Chicago, IL: AbbVie Inc; 2022.
VENCLEXTA® (venetoclax tablets) Prescribing Information. North Chicago, IL: AbbVie Inc; 2022.
CALQUENCE® (acalabrutinib) Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.
CALQUENCE® (acalabrutinib) Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.
IIMBRUVICA® (ibrutinib) Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; 2022.
IIMBRUVICA® (ibrutinib) Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; 2022.
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
Canales M, Buchholz T, Izutsu K, et al. Obinutuzumab short duration infusion in previously untreated advanced follicular lymphoma: results from the end of induction analysis of the phase IV GAZELLE study. Presented at ASCO 2021.
Canales M, Buchholz T, Izutsu K, et al. Obinutuzumab short duration infusion in previously untreated advanced follicular lymphoma: results from the end of induction analysis of the phase IV GAZELLE study. Presented at ASCO 2021.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.